NEWSROOM
Press Releases by Agendia
News
Press Releases
African-American Women More Likely to Be Diagnosed with Higher Risk Breast Cancer
Washington, D.C., June 9, 2014 – A research study led by cancer specialists at MedStar Washington Hospital Center found that African-American women frequently present with biologically less favorable subtypes of breast cancer. Researchers at the Read More
Multiple Studies on Agendia’s MammaPrint and BluePrint Tests to Be Featured at ASCO Annual Meeting
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 22, 2014– New research involving Agendia’s genomic tests MammaPrint®, BluePrint®, TargetPrint® and TheraPrint®, as well as its ColoPrint® Colon Cancer Genomic Profile, will be reported at the 2014 Read More
Molecular Subtyping with Agendia Tests Can Provide Better Guidance for Breast Cancer Treatment, New Research Reports
Presentations to American Society of Breast Surgeons Detail Clinical Insights from MammaPrint and BluePrint Genomic Tests IRVINE, CA and AMSTERDAM, May, 7 2014 – New evidence showing that the MammaPrint® and BluePrint® tests provide insights Read More
Agendia Announces New Agreement with Daiichi Sankyo to Support Oncology Drug Development
Companies Will Apply Agendia Oncology Biomarker Expertise to Daiichi Sankyo Pharmaceutical Research IRVINE, CA and AMSTERDAM, April 24, 2014 – Agendia today announced a new agreement with Daiichi Sankyo regarding oncology drug development and personalized Read More
Agendia Announces New Data at European Breast Cancer Conference that Further Supports Use of MammaPrint and BluePrint Tests
Presentation Shows MammaPrint Can Accurately Stratify Recurrence Risk up to 25 Years IRVINE, CA and AMSTERDAM, March 26, 2014 – Four scientific presentations at the 9th European Breast Cancer Conference (EBCC) underscored the international scope Read More
Agendia Co-Founder Awarded EU Prize for Women Innovators
Laura van ‘t Veer, Ph.D., Honored as Inventor of MammaPrint Breast Cancer Test IRVINE, CA and AMSTERDAM, March, 10, 2014 – Agendia co-founder Laura van ‘t Veer, Ph.D., has been awarded a 2014 Read More
Agendia Test for Molecular Subtyping of Breast Cancer Shown to Better Identify Risk of Disease Recurrence
Scientific Poster and Symposium at Miami Breast Cancer Conference Demonstrate Value of MammaPrint and BluePrint Tests Compared to First-Generation Test IRVINE, CA and AMSTERDAM, March, 11, 2014 – A scientific poster comparing Agendia’s MammaPrint® and BluePrint® Read More